ArticleKidney international reports2016
Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort.
Article in Kidney international reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 87 citations in OpenAlex.
- Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.Med (New York, N.Y.) · 2021Trial
- Integrated Multi-Tissue Omics Identifies Acylcarnitine Accumulation as Shared Metabolic Marker of Diabetic Microangiopathy With Cross-Organ Validation.Investigative ophthalmology & visual science · 2026Article
- Urinary Microcholesterol and Adverse Kidney Outcomes in CKD.Kidney international reports · 2026Article
- Chronic kidney disease induces a distinct lipidomic signature and accelerates atherosclerosis progression in a novel minipig model.Laboratory animal research · 2026Article
- Plasma Metabolites Associated with CKD Stage in Autosomal Dominant Tubulointerstitial Kidney Disease.Kidney360 · 2026Article
- Lipids and Lipid Metabolites in the Diagnosis, Risk Prediction and Treatment of Chronic Kidney Disease and Acute Kidney Injury: A Narrative Review.Kidney & blood pressure research · 2026Review
- Limitations in PPARα-dependent mitochondrial programming restrain the differentiation of human stem cell-derived β cells.Nature communications · 2025Article
- MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury.Life (Basel, Switzerland) · 2025Review
- Best practices and tools in R and Python for statistical processing and visualization of lipidomics and metabolomics data.Nature communications · 2025Review
- Lipidomics Unveils Critical Lipid Pathway Shifts in Alport Syndrome.Kidney international reports · 2025Article
- Lipidomics reveals potential biomarkers and pathophysiological insights in the progression of diabetic kidney disease.Metabolism open · 2025Article
- Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline.Diabetologia · 2025Article
- DNEA: an R package for fast and versatile data-driven network analysis of metabolomics data.BMC bioinformatics · 2024Article
- Early pregnancy serum PFAS are associated with alterations in the maternal lipidome.Environmental research · 2024Article
- Lipidomic study of kidney in a mouse model with urine flow obstruction.Scientific reports · 2024Article
- The manganese transporter SLC39A8 links alkaline ceramidase 1 to inflammatory bowel disease.Nature communications · 2024Article
- CorrelationCalculator and Filigree: Tools for Data-Driven Network Analysis of Metabolomics Data.Journal of visualized experiments : JoVE · 2023Article
- Low concentrations of medium-sized HDL particles predict incident CVD in chronic kidney disease patients.Journal of lipid research · 2023Article
- Article
- Cerebral Gray and White Matter Monogalactosyl Diglyceride Levels Rise with the Progression of Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 8 institutions in 1 country.
Funding
Abstract
introductionHuman studies report conflicting results on the predictive power of serum lipids on progression of chronic kidney disease (CKD). We aimed to systematically identify the lipids that predict progression to end-stage kidney disease.
methodsFrom the Chronic Renal Insufficiency Cohort, 79 patients with CKD stage 2 to 3 who progressed to ESKD over 6 years of follow up were selected and frequency-matched by age, sex, race, and diabetes with 121 non-progressors with less than 25% decline in estimated glomerular filtration rate (eGFR) during the follow up. The patients were randomly divided into Training and Test sets. We applied liquid chromatography-mass spectrometry-based lipidomics on visit year 1 samples.
resultsWe identified 510 lipids, of which the top 10 coincided with false discovery threshold of 0.058 in the Training set. From the top 10 lipids, the abundance of diacylglycerols (DAGs) and cholesteryl esters was lower, but that of phosphatidic acid 44:4 and monoacylglycerol (MAG) 16:0 was significantly higher in progressors. Using logistic regression models a multi-marker panel consisting of DAGs, and MAG independently predicted progression. The c-statistic of the multimarker panel added to the base model consisting of eGFR and urine protein-creatinine ratio (UPCR) as compared to that of the base model was 0.92 (95% Confidence Interval [CI]: 0.88-0.97), and 0.83 (95% CI: 0.76-0.90, P<0.01), respectively; an observation which was validated in the Test subset.
conclusionWe conclude that a distinct panel of lipids may improve prediction of progression of CKD beyond eGFR and UPCR when added to the base model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.